26P A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosine kinase inhibitors (TKIs).

MLA

Enrico, D. H., et al. “26P A Combination of Resistance Mechanisms Is Frequent in Non-Small Cell Lung Cancer (NSCLC) That Progressed to EGFR Tyrosine Kinase Inhibitors (TKIs).” Annals of Oncology, vol. 30, Nov. 2019, p. N.PAG. EBSCOhost, https://doi.org/10.1093/annonc/mdz413.031.

APA

Enrico, D. H., Lacroix, L., Rouleau, E., Scoazec, J.-Y., Loriot, Y., Tselikas, L., Jovelet, C., Planchard, D., Gazzah, A., Mezquita, L., Ngo, M., Michiels, S., Maillard, A., Massard, C., Facchinetti, F., Soria, J.-C., André, F., Vassal, G., Friboulet, L., & Besse, B. (2019). 26P A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosine kinase inhibitors (TKIs). Annals of Oncology, 30, N.PAG. https://doi.org/10.1093/annonc/mdz413.031

Chicago

Enrico, D H, L Lacroix, E Rouleau, J-Y Scoazec, Y Loriot, L Tselikas, C Jovelet, et al. 2019. “26P A Combination of Resistance Mechanisms Is Frequent in Non-Small Cell Lung Cancer (NSCLC) That Progressed to EGFR Tyrosine Kinase Inhibitors (TKIs).” Annals of Oncology 30 (November): N.PAG. doi:10.1093/annonc/mdz413.031.